

# SinaDoxosome



## Breast cancer

Systemic treatment for recurrent or stage 4 HER2 negative breast cancer

Pegylated liposomal doxorubicin (40 mg/m<sup>2</sup> every 28 days. On day one of cycle)



### PLD

50 mg/m<sup>2</sup> every 4 weeks



Versus

### Doxorubicin

60 mg/m<sup>2</sup> every 3 weeks



### Results:



- Less frequent dosing schedule
- Decreased risk of cardiotoxicity (7% versus 26%)
- Decreased rate of nausea (37% versus 53%)
- Decreased rate of vomiting (19% versus 31%)
- Lower rate of alopecia (20% versus 66%)
- Lower rate of neutropenia (4% versus 10%)
- Higher rate of palmar-plantar erythrodysesthesia (48% versus 2%)
- Higher rate of stomatitis (22% versus 15%)
- Higher rate of mucositis (23% versus 13%)